MKI67 and B-cell chronic lymphocytic leukemia: Treatment with AT-1 monoclonal antibody (mAb) produced a concentration-dependent decrease in CLL proliferation while leaving the Th cell Ki67+ population largely intact (Figures 4B and 4C).